{
    "title": "108_hr2629",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``New Aid for Trustworthy, Affordable \nDrugs Act (NAFTA Drugs Act)''.\n\nSEC. 2. HARMONIZATION OF DRUG LAWS REGARDING IMPORTATION INTO NAFTA \n              COUNTRIES FROM OTHER NAFTA COUNTRIES.\n\n    Section 803 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n383) is amended by adding at the end the following subsection:\n    ``(d)(1) Consistent with the North American Free Trade Agreement \napproved by the Congress under section 101(a) of Public Law 103-182 \n(referred to in this subsection as `NAFTA'), the United States Trade \nRepresentative shall seek to enter into agreements with other NAFTA \ncountries to harmonize regulatory requirements for drugs such that \ndrugs approved for commercial distribution in any NAFTA country may be \nimported or exported from any NAFTA country into any NAFTA country.\n    ``(2) The United States Trade Representative shall carry out this \nsubsection in consultation with the Secretary and the Commissioner of \nFood and Drugs.\n    ``(3) The United States Trade Representative may enter into a \nharmonization agreement under paragraph (1) only if such Representative \ndetermines as follows:\n            ``(A) That the proposed agreement provides for regulatory \n        standards for drugs that are consistent with the requirements \n        of this Act.\n            ``(B) That the proposed agreement provides for--\n                    ``(i) the display of a seal on the labeling of the \n                drugs involved, whose purpose is to indicate that the \n                drugs meet the standards of the harmonization agreement \n                and may be imported as provided in paragraph (1);\n                    ``(ii) uniform standards applicable to the display \n                of such a seal in any NAFTA country; and\n                    ``(iii) approval of such a seal by the appropriate \n                health authority in any NAFTA country before the \n                display of the seal in that country, for the purpose of \n                ensuring that the seal complies with the uniform \n                standards described in clause (ii).\n            ``(C) That the proposed agreement provides that a drug may \n        not be imported into a NAFTA country from another NAFTA country \n        unless the labeling of the drug bears a seal described in \n        subparagraph (B).\n            ``(D) That the proposed agreement provides for a system of \n        unique tracking numbers to indicate--\n                    ``(i) the manufacturer of the drug involved, the \n                NAFTA country of origin, and the wholesale distributors \n                of the drug; and\n                    ``(ii) in the case of a prescription drug, the \n                pharmacy that dispenses the drug.\n            ``(E) That the proposed agreement provides for--\n                    ``(i) the placement of a seal described in \n                subparagraph (B) on the labeling of a drug only by a \n                pharmacy registered in accordance with this \n                subparagraph;\n                    ``(ii) registration of pharmacies in each NAFTA \n                country by the appropriate health authority in each \n                such country for the purpose of authorizing such \n                pharmacies to place a seal described in subparagraph \n                (B) on the labeling of drugs; and\n                    ``(iii) uniform standards applicable to such \n                registration.\n            ``(F) That the proposed agreement--\n                    ``(i) requires drug manufacturers to reimburse the \n                Secretary of Health and Human Services for benefits \n                derived by such manufacturers from research performed \n                by the National Institutes of Health; and\n                    ``(ii) authorizes use of such reimbursement to pay \n                the expenses incurred by the Food and Drug \n                Administration in approving seals under subparagraph \n                (B) and registering pharmacies under subparagraph (E).\n            ``(G) That the proposed agreement prohibits any \n        discrimination by any person in the manufacture, distribution, \n        or sale of any drug that bears a seal described in subparagraph \n        (B), on the basis of a prospective customer's citizenship or \n        residency in a NAFTA country, or on the basis of a request for \n        shipment of the drug to any NAFTA country.\n    ``(4) The authority of the United States Trade Representative to \nenter a harmonization agreement under paragraph (1) terminates one year \nafter the date of the enactment of New Aid for Trustworthy, Affordable \nDrugs Act (NAFTA Drugs Act).\n    ``(5) For purposes of this subsection, the term `NAFTA country' \nmeans each of the United States, Canada, and the United Mexican \nStates--\n            ``(A) for such time as NAFTA is in force with respect to \n        such country; and\n            ``(B) in the case of each of Canada and the United Mexican \n        States, for such time as the United States applies NAFTA to \n        such country.''."
}